A review of the current breast cancer trials;Gibt es fortschritte in der medikamentösen therapie von patientinnen mit mammakarzinom?

Wiener Klinische Wochenschrift

Volumn 113, Issue 9, 2001, Pages 306-320

  Wenzel, C ^a   Schmidinger, M ^a   Huber, H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; Cytostatic chemotherapy; Hormonal therapy; Review

Indexed keywords

ANASTROZOLE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; FOLLITROPIN; FORMESTANE; FULVESTRANT; GEMCITABINE; GOSERELIN; IDOXIFENE; IRINOTECAN; LETROZOLE; LOSOXANTRONE; LUTEINIZING HORMONE; METHOTREXATE; NAVELBINE; PACLITAXEL; RALOXIFENE; RALTITREXED; TAMOXIFEN; TOPOTECAN; TOREMIFENE; TRASTUZUMAB; UFT; VOROZOLE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CARCINOMA IN SITU; CLINICAL TRIAL; DRUG CHOICE; HUMAN; MASTECTOMY; ONCOGENE NEU; OVARIECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; REVIEW; TREATMENT INDICATION;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRIA; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; DRUG APPROVAL; FEMALE; HUMANS; IMMUNOTHERAPY; PALLIATIVE CARE; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS;

EID: 0035971461     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Malignant tumors of the breast
2. Declining cancer rates in the 1990s
3. Variations in survival from breast cancer in Europe by age and country, 1978-1989
4. Phase III trial of taxol, an active drug in the treatment of metastatic breast cancer
5. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer
6. The role of taxanes in the management of breast cancer
7. Meeting highlights: International consensus panel on the treatment of primary breast cancer
8. NIH Consensus Statements: Adjuvant therapy for breast cancer
9. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
10. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6
11. Polychemotherapy for early breast cancer: An overview of the randomised trials
12. A clinical trial of intensive CEF versus CMF in premenopausal women with node positive breast cancer
13. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16
14. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
15. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC)
16. Hormonal therapy of breast cancer
17. Zoladex (Goserelin) vs. CMF as adjuvant therapy in pre-/perimenopausal node-positive breast cancer
18. Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal Stage I and II hormon-responsive breast cancer patients: Four-year-results of Austrian Breast Cancer Study Group (ABCSG) Trial 5
19. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT0101)
20. Current and future directions in medical therapy for breast carcinoma
21. Tamoxifen vs. Tamoxifen plus Aminoglutethemide for stage I and II receptor-positive postmenopausal node-negative or node-positive breast cancer patients: Four-year results of a randomized trial of the Austrian Breast Cancer Study Group (ABCSG)
22. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute
23. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
24. Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0, M0)
25. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel
26. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil,doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
27. Preoperative endocrine therapy for breast cancer
28. Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer
29. Neo-adjuvant treatment of postmenopausal breast cancer patients and impact on breast-conserving surgery: A double blind randomized study comparing letrozole to tamoxifen - The Letrozole Neo-Adjuvant Breast Cancer Study Group
30. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer
31. Randomised trial of high-dose chemotherapy and haemopoietic progenitor cell support in operable breast cancer with extensive axillary lymph-node involvment
32. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13
33. Results from a randomized adjuvant breast cancer study with high-dose chemotherapy with CTC supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy
34. Critique of the high-dose chemotherapy studies in breast cancer: A positive look at the data
35. Stellenwert der hochdosistherapie beim mammakarzinom
36. Consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999
37. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
38. State-of-the-art chemotherahy for advanced breast cancer
39. Treatment of breast cancer
40. Cytotoxic and hormonal treatment for metastatic breast cancer: A systemic review of randomized trials involving 31,510 women
41. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: A reference
42. Recent advances in systemic therapy for breast cancer
43. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
44. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients
45. Docetaxel monotherapy in heavily pretreated metastatic breast cancer: Multicenter, community-based feasibility trial
46. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over
47. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
48. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196
49. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with breast cancer
50. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients
51. Doxorubicin / taxane combinations: Cardiac toxicity and pharmacokinetics
52. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamid (AC) as first line chemotherapy for MBC
53. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer
54. Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines
55. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Group
56. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology group Study
57. An individual patient-based metaanalysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer
58. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1
59. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study
60. Therapy in premenopausal women with advanced, oestrogen positive or/and progesteron positive breast cancer: Surgical oophorectomy versus the LHRH analogue, Zoladex
61. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study
62. Activity of exemestane in metastatic breast cancer after failure of non-steroidal aromatase inhibitors: A phase II trial
63. Letrozole is superior to tamoxifen as first-line hormonal treatment of postmenopausal women with locally advanced or metastatic breast cancer (bc)
64. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American Multicenter Randomized Trial
65. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen and arimidex randomized group efficacy and tolerability study
66. Aromatase inhibitors for breast cancer - Further progress
67. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update on a combined analysis of data from two mature phase III trials: Arimidex Study Group
68. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
69. Anastrozole, a potent and selective aromatase inhibitor, versus megestrole acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials
70. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a Phase III randomized double-blind trial
71. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group
72. Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group protocol 8081
73. Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081
74. Much ado about not ..... enough data: High-dose chemotherapy with autologous stem cell rescue for breast cancer
75. High-dose chemotherapy with autologous hematopoetic stem-cell support for breast cancer in North America
76. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer
77. High-dose chemotherapy (HD-CT) with hematopoetic stem cells transplantation (HSCT) for metastatic breast cancer (MBC): Results of the French Protocol PEGASE 04
78. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer
79. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neuoncogene
80. The neu-oncogene: Signaltransduction pathways, transformation mechanisms and evolving therapies
81. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms
82. HER-2/neu gene amplification characterized by fluorescence in situ hybridization poor prognosis in node-negative breast carcinomas
83. Prognostic importance of c-erbB-2 expression in breast cancer
84. ERBB2 oncogene in human breast cancer and its clinical significance
85. Prognostic and predictive value of c-erbB-2 over-expression in primary breast cancer, alone in combination with other prognostic markers
86. Docetaxel (Taxotere) in HER2-positive patients and in combination with Trastuzumab (Herceptin)
87. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
88. c-erb B2 over-expression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
89. Cell biological factors associated with the response of breast cancer to systemic treatment
90. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
91. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
92. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
93. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
94. Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
95. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
96. First-line, non-hormonal, treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (Trastuzumab, humanized Anti-HER2 antibody)
97. Addition of herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+ /MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial
98. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin)
99. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifen
100. A brief review of the current prevention trials and proposals for future trials
101. Assessing the risk of breast cancer
102. Tamoxifen for the prevention of breast cancer
103. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
104. National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial: A reflective commentary
105. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
106. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
107. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten year results
108. Risk-adapted chemotherapy in the adjuvant setting of breast cancer
109. American Society of Clinical Oncology Guideline on the role of bisphosphonates in breast cancer
110. A phase II trial of single-agent rhuMAb VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) in patients with relapsed metastatic breast cancer
111. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer
112. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
113. Tumor regression of human breast carcinomas by combination therapy of anti-bcl-2 antisense oligonucleotide and chemotherapeutic drugs
114. Tamoxifen prevention of breast cancer: An instance of the fingerpost
115. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study